Introduction. Endourological kidney-sparing treatment is the first-line option for low-risk upper tract urothelial carcinoma (UTUC), but it is also offered to selected high-risk patients. The prognostic value of the EAU risk stratification after kidney-sparing treatment, and in particular of the distinction between strong and weak high-risk criteria, is still poorly known. Aim of the study. To evaluate the oncological outcomes of endourological kidney-sparing treatment for UTUC and to compare them between low-risk and high-risk patients according to the EAU 2026 risk stratification; as an exploratory aim, to assess whether, among high-risk patients, the distinction between strong and weak criteria identifies two groups with different prognosis. Materials and methods. Retrospective single-centre study of patients who underwent endourological kidney-sparing treatment for UTUC at the Urology Unit of the University Hospital of Padua between March 2013 and June 2025. Patients with occult UTUC, diagnosed on cytology only, were described separately. Endpoints were ipsilateral recurrence-free survival (RFS), progression-free survival (PFS), nephroureterectomy-free survival (RNU-FS), bladder recurrence-free survival (BC-RFS), overall survival (OS) and cancer-specific mortality (CSM). Kaplan-Meier curves with the log-rank test, univariable and exploratory multivariable Cox models and, for CSM, cumulative incidence with Gray's test were used. Renal function and ureteral strictures were also assessed. Results. Of 91 patients, 7 had occult UTUC. The main population included 84 patients: 30 (36%) low-risk and 54 (64%) high-risk, 33 of whom had strong criteria and 21 weak criteria only. At a median follow-up of 64 months, 64% of patients had an ipsilateral recurrence and 26% underwent nephroureterectomy. At 5 years, RFS was 28%, PFS 61%, RNU-FS 73%, BC-RFS 37% and OS 78%, with a CSM of 12%. High-risk patients had worse RFS (19% vs 45%; HR 2.68), PFS (53% vs 75%; HR 3.49), RNU-FS (67% vs 86%; HR 4.16) and BC-RFS (28% vs 52%; HR 1.99). All UTUC deaths occurred in high-risk patients (5-year CSM 19% vs 0%; p = 0.03), whereas OS did not differ between groups. The association with recurrence and progression persisted in multivariable analysis (HR 2.50 and 3.86) and in sensitivity analyses. Patients with strong criteria had the highest risk of recurrence, progression and nephroureterectomy (HR 3.10, 4.15 and 5.25), whereas those with weak criteria only had an intermediate risk, not significantly different from low-risk patients. Overall, 33% of patients lost the treated renal unit; in patients with a preserved kidney, median eGFR decreased from 71 to 60 ml/min. Conclusions. Endourological kidney-sparing treatment preserves the kidney in most patients, at the cost of frequent ipsilateral recurrences. The EAU 2026 risk stratification retains its prognostic value after kidney-sparing treatment. Kidney-sparing treatment remains the first choice in low-risk patients and an option to be discussed in high-risk patients with weak criteria only; in patients with strong criteria it should be reserved for selected cases, with close follow-up and a low threshold for conversion to nephroureterectomy.
Introduzione. Il trattamento endourologico conservativo è l'opzione di prima scelta nel carcinoma uroteliale dell'alta via escretrice (UTUC) a basso rischio, ma viene proposto anche a Pazienti ad alto rischio selezionati. Il valore prognostico della stratificazione del rischio EAU dopo trattamento conservativo, e in particolare della distinzione tra criteri di alto rischio forti e deboli, è ancora poco conosciuto. Scopo dello studio. Valutare gli esiti oncologici del trattamento endourologico conservativo dell'UTUC e confrontarli tra i Pazienti a basso e ad alto rischio secondo la stratificazione EAU 2026; come obiettivo esplorativo, valutare se nei Pazienti ad alto rischio la distinzione tra criteri forti e deboli identifichi due gruppi a prognosi diversa. Materiali e metodi. Studio retrospettivo monocentrico sui Pazienti sottoposti a trattamento endourologico conservativo per UTUC presso l'U.O.C. di Urologia dell'Azienda Ospedaliera-Università di Padova tra marzo 2013 e giugno 2025. I Pazienti con UTUC occulto, diagnosticato solo sulla base della citologia, sono stati descritti separatamente. Gli endpoint erano la sopravvivenza libera da recidiva omolaterale (RFS), da progressione (PFS), da nefroureterectomia (RNU-FS) e da recidiva vescicale (BC-RFS), la sopravvivenza globale (OS) e la mortalità cancro-specifica (CSM). Sono state usate le curve di Kaplan-Meier con il test log-rank, i modelli di Cox univariabili e multivariabili esplorativi e, per la CSM, l'incidenza cumulativa con il test di Gray. Sono stati valutati anche la funzione renale e le stenosi ureterali. Risultati. Su 91 Pazienti, 7 avevano un UTUC occulto. La popolazione principale comprendeva 84 Pazienti: 30 (36%) a basso rischio e 54 (64%) ad alto rischio, di cui 33 per criteri forti e 21 per soli criteri deboli. Con un follow-up mediano di 64 mesi, il 64% dei Pazienti ha avuto una recidiva omolaterale e il 26% è stato sottoposto a nefroureterectomia. A 5 anni la RFS era del 28%, la PFS del 61%, la RNU-FS del 73%, la BC-RFS del 37% e l'OS del 78%, con una CSM del 12%. I Pazienti ad alto rischio avevano una RFS (19% contro 45%; HR 2,68), una PFS (53% contro 75%; HR 3,49), una RNU-FS (67% contro 86%; HR 4,16) e una BC-RFS (28% contro 52%; HR 1,99) peggiori. Tutte le morti per UTUC si sono verificate nei Pazienti ad alto rischio (CSM a 5 anni 19% contro 0%; p = 0,03), mentre l'OS non differiva tra i gruppi. L'associazione con recidiva e progressione si è mantenuta all'analisi multivariabile (HR 2,50 e 3,86) e nelle analisi di sensibilità. I Pazienti con criteri forti avevano il rischio più alto di recidiva, progressione e nefroureterectomia (HR 3,10, 4,15 e 5,25), mentre quelli con soli criteri deboli avevano un rischio intermedio, non significativamente diverso dal basso rischio. Il 33% dei Pazienti ha perso l'unità renale trattata; nei Pazienti con rene conservato l'eGFR mediano è sceso da 71 a 60 ml/min. Conclusioni. Il trattamento endourologico conservativo permette di preservare il rene nella maggior parte dei Pazienti, a fronte di recidive omolaterali frequenti. La stratificazione EAU 2026 mantiene il suo valore prognostico anche dopo trattamento conservativo. Il trattamento conservativo resta la prima scelta nei Pazienti a basso rischio ed è un'opzione da discutere nei Pazienti ad alto rischio per soli criteri deboli; nei Pazienti con criteri forti va riservato a casi selezionati, con un follow-up stretto e una bassa soglia di conversione a nefroureterectomia.
Outcome oncologici del trattamento endourologico dei tumori dell'alta via escretrice: esperienza di un centro di terzo livello
BASSO, GIOVANNI
2024/2025
Abstract
Introduction. Endourological kidney-sparing treatment is the first-line option for low-risk upper tract urothelial carcinoma (UTUC), but it is also offered to selected high-risk patients. The prognostic value of the EAU risk stratification after kidney-sparing treatment, and in particular of the distinction between strong and weak high-risk criteria, is still poorly known. Aim of the study. To evaluate the oncological outcomes of endourological kidney-sparing treatment for UTUC and to compare them between low-risk and high-risk patients according to the EAU 2026 risk stratification; as an exploratory aim, to assess whether, among high-risk patients, the distinction between strong and weak criteria identifies two groups with different prognosis. Materials and methods. Retrospective single-centre study of patients who underwent endourological kidney-sparing treatment for UTUC at the Urology Unit of the University Hospital of Padua between March 2013 and June 2025. Patients with occult UTUC, diagnosed on cytology only, were described separately. Endpoints were ipsilateral recurrence-free survival (RFS), progression-free survival (PFS), nephroureterectomy-free survival (RNU-FS), bladder recurrence-free survival (BC-RFS), overall survival (OS) and cancer-specific mortality (CSM). Kaplan-Meier curves with the log-rank test, univariable and exploratory multivariable Cox models and, for CSM, cumulative incidence with Gray's test were used. Renal function and ureteral strictures were also assessed. Results. Of 91 patients, 7 had occult UTUC. The main population included 84 patients: 30 (36%) low-risk and 54 (64%) high-risk, 33 of whom had strong criteria and 21 weak criteria only. At a median follow-up of 64 months, 64% of patients had an ipsilateral recurrence and 26% underwent nephroureterectomy. At 5 years, RFS was 28%, PFS 61%, RNU-FS 73%, BC-RFS 37% and OS 78%, with a CSM of 12%. High-risk patients had worse RFS (19% vs 45%; HR 2.68), PFS (53% vs 75%; HR 3.49), RNU-FS (67% vs 86%; HR 4.16) and BC-RFS (28% vs 52%; HR 1.99). All UTUC deaths occurred in high-risk patients (5-year CSM 19% vs 0%; p = 0.03), whereas OS did not differ between groups. The association with recurrence and progression persisted in multivariable analysis (HR 2.50 and 3.86) and in sensitivity analyses. Patients with strong criteria had the highest risk of recurrence, progression and nephroureterectomy (HR 3.10, 4.15 and 5.25), whereas those with weak criteria only had an intermediate risk, not significantly different from low-risk patients. Overall, 33% of patients lost the treated renal unit; in patients with a preserved kidney, median eGFR decreased from 71 to 60 ml/min. Conclusions. Endourological kidney-sparing treatment preserves the kidney in most patients, at the cost of frequent ipsilateral recurrences. The EAU 2026 risk stratification retains its prognostic value after kidney-sparing treatment. Kidney-sparing treatment remains the first choice in low-risk patients and an option to be discussed in high-risk patients with weak criteria only; in patients with strong criteria it should be reserved for selected cases, with close follow-up and a low threshold for conversion to nephroureterectomy.| File | Dimensione | Formato | |
|---|---|---|---|
|
Tesi_Giovanni_Basso_definitiva.pdf
Accesso riservato
Dimensione
1.39 MB
Formato
Adobe PDF
|
1.39 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/119589